ABT Stock Recent News

Abbott Laboratories (NYSE:ABT ) Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ET Company Participants Mike Comilla - VP, IR Robert Ford - Chairman and CEO Phil Boudreau - EVP, Finance and CFO Conference Call Participants Robert Marcus - JPMorgan Larry Biegelsen - Wells Fargo Travis Steed - BofA Securities David Roman - Goldman Sachs Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Josh Jennings - TD Cowen Marie Thibault - BTIG Operator Good morning, and thank you for standing by. Welcome to Abbott's First Quarter 2025 Earnings Conference Call.

Abbott Laboratories (NYSE:ABT) reported a profit beat for the first quarter driven by growth in its medical devices and diabetes care segments, as revenue fell short of estimates. The healthcare company beat earnings estimates by $0.02 with earnings per share (EPS) of $1.09 as revenue of $10.36 billion missed expectations of $10.41 billion.

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 2% on Wednesday.

Abbott (ABT) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $0.98 per share a year ago.

Abbott stock slipped early Wednesday after the health giant reported light first-quarter sales, though profit beat expectations.

Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments.

Abbott Labs posts first-quarter adjusted profit that topped analysts' estimates.

Abbott Laboratories beat Wall Street estimates for first-quarter profit on Wednesday, buoyed by strong demand for diabetes care and other medical devices.

First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09 First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1 Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increase Reported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increase ABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ --  Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2025.